BRPI0607803A2 - forma de dosagem oral compreendendo rosiglitazona - Google Patents

forma de dosagem oral compreendendo rosiglitazona

Info

Publication number
BRPI0607803A2
BRPI0607803A2 BRPI0607803-6A BRPI0607803A BRPI0607803A2 BR PI0607803 A2 BRPI0607803 A2 BR PI0607803A2 BR PI0607803 A BRPI0607803 A BR PI0607803A BR PI0607803 A2 BRPI0607803 A2 BR PI0607803A2
Authority
BR
Brazil
Prior art keywords
dosage form
composition
oral dosage
rosiglitazone
pharmaceutically acceptable
Prior art date
Application number
BRPI0607803-6A
Other languages
English (en)
Inventor
Joanne Heafield
Vincenzo Re
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of BRPI0607803A2 publication Critical patent/BRPI0607803A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMA DE DOSAGEM ORAL COMPREENDENDO ROSIGLITAZONA. Uma forma de dosagem oral, tal como um comprimido em bicamada compreendendo uma primeira camada de uma primeira composição e uma segunda camada de uma segunda composição, cada composição compreendendo 5-[4-[2-(N-metil-N-(2 piridil)amino)etóxi]benzil]tiazolidina-2,4-diona ou um sal ou solvato farmaceuticamente aceitável deste, ('a droga') e um veículo farmaceuticamente aceitável para este, em que a primeira e a segunda composição são organizadas para liberar droga em taxas de liberação diferentes na administração; um processo para preparar tal forma de dosagem e o uso de tal forma de dosagem na medicina.
BRPI0607803-6A 2005-02-07 2006-02-03 forma de dosagem oral compreendendo rosiglitazona BRPI0607803A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502475.7A GB0502475D0 (en) 2005-02-07 2005-02-07 Novel compositions
PCT/EP2006/000997 WO2006087116A1 (en) 2005-02-07 2006-02-03 Oral dosage form comprising rosiglitazone

Publications (1)

Publication Number Publication Date
BRPI0607803A2 true BRPI0607803A2 (pt) 2009-06-13

Family

ID=34355898

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607803-6A BRPI0607803A2 (pt) 2005-02-07 2006-02-03 forma de dosagem oral compreendendo rosiglitazona

Country Status (16)

Country Link
US (1) US20080166408A1 (pt)
EP (1) EP1855671A1 (pt)
JP (1) JP2008543723A (pt)
KR (1) KR20070110016A (pt)
CN (1) CN101155586A (pt)
AU (1) AU2006215854A1 (pt)
BR (1) BRPI0607803A2 (pt)
CA (1) CA2595411A1 (pt)
EA (1) EA200701681A1 (pt)
GB (1) GB0502475D0 (pt)
IL (1) IL184790A0 (pt)
MA (1) MA29281B1 (pt)
MX (1) MX2007009492A (pt)
NO (1) NO20074407L (pt)
TW (1) TW200700063A (pt)
WO (1) WO2006087116A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
EA201170230A1 (ru) * 2008-07-18 2011-08-30 Вэлиант Фармасьютикалс Интернешнл Препарат с модифицированной кинетикой высвобождения и способы его использования
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
JP5914701B2 (ja) * 2012-02-22 2016-05-11 デュシネイ・インコーポレイテッド ドキシラミンおよびピリドキシン、ならびに／またはその代謝物もしくは塩の製剤
PL3024466T3 (pl) 2013-07-22 2018-08-31 Duchesnay Inc. Kompozycja do kontrolowania nudności i wymiotów
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
JP7246384B2 (ja) * 2017-10-25 2023-03-27 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 遅延放出デフェリプロン錠剤及びその使用法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AR045330A1 (es) * 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations

Also Published As

Publication number Publication date
MX2007009492A (es) 2007-09-19
CA2595411A1 (en) 2006-08-24
MA29281B1 (fr) 2008-02-01
WO2006087116A1 (en) 2006-08-24
KR20070110016A (ko) 2007-11-15
JP2008543723A (ja) 2008-12-04
IL184790A0 (en) 2007-12-03
CN101155586A (zh) 2008-04-02
EA200701681A1 (ru) 2007-12-28
TW200700063A (en) 2007-01-01
US20080166408A1 (en) 2008-07-10
AU2006215854A1 (en) 2006-08-24
NO20074407L (no) 2007-08-29
GB0502475D0 (en) 2005-03-16
EP1855671A1 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
BRPI0616077B8 (pt) composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
WO2007126362A8 (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
NO20074514L (no) Oral doseringsform omfattende rosiglitazon
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
NO20074407L (no) Oral doseringsform omfattende rosiglitazon
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
AR059225A1 (es) Sal de citrato, proceso de preparacion y su actividad en terapia
BRPI0607804A2 (pt) braçadeira de lámina despeladora com ranhuras de saìda de gordura
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
ECSP034469A (es) Compuesto farmaceutico novedoso
CY1107252T1 (el) Τρυγικο αλας παραγωγου της θειζολιδινοδιονης
BR0111536A (pt) Sal de tiazolidinediona para tratamento de diabetes mellitus
GB0021784D0 (en) Novel pharmaceutical
BR0112984A (pt) Sais tartarato de derivado de tiazolidinodiona
CY1107421T1 (el) Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης
CY1107767T1 (el) Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
AP2002002684A0 (en) 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical
AR118314A1 (es) Composición farmacéutica
CY1106397T1 (el) Βενζολοσουλφονικη 5-(4-(2-(ν-μεθυλο-ν-(2-πυριδιλ)αμινο)αιθοξυ)βενζυλο) θειαζολιδινο-2,4-διονη ˙ διepγασια παρασκευης αυτης ˙ πολυμορφες ι,ιι και ιιι αυτης ˙ και χρηση αυτης ως φαρμακευτικο δραστικο συστατικο
ECSP003434A (es) Nuevos compuestos
TH84984B (th) รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน
TH72850A (th) สารผสมชนิดใหม่
ECSP003438A (es) Nuevos compuestos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SMITHKLINE BEECHAM (CORK) LIMITED (IE)

Free format text: TRANSFERIDO DE: SB PHARMCO PUERTO RICO INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.